{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:05:07Z","timestamp":1791407107428,"version":"4.3.3"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tjpad.2025.100458","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:33:04Z","timestamp":1767231184000},"page":"100458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Tianle","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3670-4945","authenticated-orcid":false,"given":"R. Matthew","family":"Hutchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Rubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gersham","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Molenberghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha Budd","family":"Haeberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100458_bib0001","unstructured":"Advancing health through innovation: new drug therapy approvals 2023. Center for Drug Evaluation and Research. Food and Drug Administration; September 19, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0002","article-title":"Biologic Accelerated Approvals Based on a Surrogate Endpoint","volume":"19","author":"Drug","year":"2024","journal-title":"US Food and Drug Administration"},{"key":"10.1016\/j.tjpad.2025.100458_bib0003","unstructured":"U.S. Food and Drug Administration. Accelerated approval. 2023 https:\/\/www.fda.gov\/patients\/fast-track-breakthrough-therapy-accelerated-approval-priority-review\/accelerated-approval. September 19, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0004","unstructured":"U.S. Food and Drug Administration. Surrogate endpoint resources for drug and biologic development. 2018 https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development. September 18, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0005","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/1078-0432.CCR-03-0781","article-title":"Approval summary for bortezomib for injection in the treatment of multiple myeloma","volume":"10","author":"Bross","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tjpad.2025.100458_bib0006","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/bimj.201400049","article-title":"Statistical evaluation of surrogate endpoints with examples from cancer clinical trials","volume":"58","author":"Buyse","year":"2016","journal-title":"Biom J"},{"key":"10.1016\/j.tjpad.2025.100458_bib0007","unstructured":"European Medicines Agency. Conditional marketing Authorization. 2004 https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/conditional-marketing-authorisation. September 19, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer's Disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.tjpad.2025.100458_bib0009","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease","volume":"18","author":"Khan","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115522","article-title":"Alzheimer's disease: insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs","volume":"211","author":"Monteiro","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0011","doi-asserted-by":"crossref","first-page":"371","DOI":"10.14283\/jpad.2021.23","article-title":"Diagnosis of early Alzheimer's Disease: clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100458_bib0012","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/bph.14581","article-title":"A short perspective on the long road to effective treatments for Alzheimer's disease","volume":"176","author":"Reynolds","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0013","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/alz.12192","article-title":"Hypothesis: tau pathology is an initiating factor in sporadic Alzheimer's disease","volume":"17","author":"Arnsten","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0014","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer's disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.tjpad.2025.100458_bib0015","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a024539","article-title":"Genetics of \u03b2-amyloid precursor protein in Alzheimer's disease","volume":"7","author":"Tcw","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11051411","article-title":"The roles of the amyloid beta monomers in physiological and pathological conditions","volume":"11","author":"Schreiner","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.tjpad.2025.100458_bib0017","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12987-022-00318-y","article-title":"Decreased CSF clearance and increased brain amyloid in Alzheimer's disease","volume":"19","author":"Li","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.tjpad.2025.100458_bib0018","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","article-title":"Amyloid \u03b2 oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis","volume":"129","author":"Viola","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0019","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","article-title":"Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis","volume":"71","author":"Bloom","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0020","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1007\/s11064-024-04178-w","article-title":"Biomarkers and target-specific small-molecule drugs in Alzheimer's diagnostic and therapeutic research: from amyloidosis to tauopathy","volume":"49","author":"Sheng","year":"2024","journal-title":"Neurochem Res"},{"key":"10.1016\/j.tjpad.2025.100458_bib0021","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","article-title":"Revised criteria for the diagnosis and staging of Alzheimer's disease","volume":"30","author":"Jack","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0022","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0023","article-title":"Predicting cognitive decline: which is more useful, baseline amyloid levels or longitudinal change?","volume":"41","author":"Chen","year":"2024","journal-title":"NeuroImage: Clin"},{"key":"10.1016\/j.tjpad.2025.100458_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101728","article-title":"Nutrients and amyloid \u03b2 status in the brain: a narrative review","volume":"81","author":"D\u00edaz","year":"2022","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.tjpad.2025.100458_bib0025","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jalz.2017.03.008","article-title":"Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease","volume":"13","author":"Brown","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ana.25117","article-title":"Effect of sleep on overnight cerebrospinal fluid amyloid \u03b2 kinetics","volume":"83","author":"Lucey","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0027","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-220765","article-title":"The association of kidney function with plasma amyloid-\u03b2 levels and brain amyloid deposition","volume":"92","author":"Sedaghat","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100458_bib0028","unstructured":"Amyvid (florbetapir F-18) [prescribing information]. Lilly; Indianapolis, IN. 2023."},{"key":"10.1016\/j.tjpad.2025.100458_bib0029","unstructured":"Vizamyl (flutemetamaol F-18) [prescribing information]. GE Healthcare; Arlington Heights, IL. 2017."},{"key":"10.1016\/j.tjpad.2025.100458_bib0030","unstructured":"Neuraceq (florbetaben) [prescribing information]. Life Molecular; Hampshire, UK. 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0031","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1007\/s00259-022-05784-y","article-title":"Quantification of amyloid PET for future clinical use: a state-of-the-art review","volume":"49","author":"Pemberton","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.tjpad.2025.100458_bib0032","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.25968","article-title":"Diagnostic accuracy of amyloid versus (18) F-fluorodeoxyglucose positron emission tomography in autopsy-confirmed dementia","volume":"89","author":"Lesman-Segev","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0033","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13195-023-01332-4","article-title":"Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study","volume":"15","author":"Bader","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100458_bib0034","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/psp4.12862","article-title":"Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease","volume":"11","author":"Hayato","year":"2022","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jalz.2019.09.023","article-title":"Population pharmacokinetic\/pharmacodynamic analyses of BAN2401 in patients with early Alzheimer's disease: correlation of BAN2401 exposure, PET standard uptake value ratio, and cognitive outcomes","volume":"15","author":"Schuck","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0036","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","article-title":"The evolution of preclinical Alzheimer's disease: implications for prevention trials","volume":"84","author":"Sperling","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.tjpad.2025.100458_bib0037","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3233\/JAD-142910","article-title":"Patterns of cognitive decline prior to dementia in persons with mild cognitive impairment","volume":"47","author":"Cloutier","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100458_bib0038","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1017\/S1041610222000047","article-title":"Global cognitive trajectory patterns in Alzheimer's disease","volume":"36","author":"Cohen","year":"2024","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.tjpad.2025.100458_bib0039","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.1002\/alz.13858","article-title":"A cross-sectional study of \u03b1-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: prevalence and associations with Alzheimer's disease biomarkers and cognitive function","volume":"20","author":"Tosun","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00401-023-02657-y","article-title":"Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without lewy bodies and Parkinson's disease with dementia","volume":"147","author":"Van Der Gaag","year":"2024","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0041","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41467-022-35712-5","article-title":"Forecasting individual progression trajectories in Alzheimer's disease","volume":"14","author":"Maheux","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.tjpad.2025.100458_bib0042","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/alz.12773","article-title":"Why a clinical trial is as good as its outcome measure: a framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease","volume":"19","author":"Jutten","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0043","unstructured":"Early Alzheimer's disease: developing drugs for treatment - guidance for industry. 2024 https:\/\/www.fda.gov\/media\/110903\/download. September 17, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0044","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1159\/000511506","article-title":"Lessons learnt from the second generation of anti-amyloid monoclonal antibodies clinical trials","volume":"49","author":"Tian Hui Kwan","year":"2020","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.tjpad.2025.100458_bib0045","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/cpt.2536","article-title":"Toward bridging unmet medical need in early Alzheimer's disease: an evaluation of beta-amyloid (A\u03b2) plaque burden as a potential drug development tool","volume":"111","author":"Zhu","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.tjpad.2025.100458_bib0046","unstructured":"Aduhelm (aducanumab-avwa) [prescribing information]. Biogen; Cambridge, MA. 2022."},{"key":"10.1016\/j.tjpad.2025.100458_bib0047","unstructured":"Leqembi (lecanemab-irmb) [prescribing information]. Eisai; Nutley, NJ. 2023."},{"key":"10.1016\/j.tjpad.2025.100458_bib0048","unstructured":"Kisunla (donanemab-azbt) [prescribing information]. Eli Lilly; Indianapolis, IN. 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0049","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100458_bib0050","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.tjpad.2025.100458_bib0092","unstructured":"Biogen Idec presents positive interim results from phase 1B study of investigational Alzheimer\u2019s Disease treatment Aducanumab (BIIB037) at 2015 AD\/PD\u2122 conference. 2015 https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-idec-presents-positive-interim-results-phase-1b-study. August 13, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces a\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tjpad.2025.100458_bib0093","unstructured":"Biogen presents data from phase 1b study of investigational Alzheimer\u2019s Disease treatment Aducanumab at 2016 Clinical Trials on Alzheimer\u2019s Disease meeting. 2016 https:\/\/investors.biogen.com\/news-releases\/news-release-details\/biogen-presents-data-phase-1b-study-investigational-alzheimers. August 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0102","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1002\/alz.13755","article-title":"Results from the long-term extension of PRIME: a randomized Phase 1b trial of aducanumab","volume":"20","author":"Chen","year":"2024","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0094","unstructured":"Eisai and Biogen announce positive topline results of the final analysis for BAN2401 at 18 months. 2018 https:\/\/investors.biogen.com\/news-releases\/news-release-details\/eisai-and-biogen-announce-positive-topline-results-final. August 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0103","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7230","article-title":"Lecanemab for patients with early Alzheimer disease: bayesian analysis of a phase 2b dose-finding randomized clinical trial","volume":"6","author":"Berry","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tjpad.2025.100458_bib0071","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1001\/jamaneurol.2022.2793","article-title":"Association of amyloid reduction after Donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial","volume":"79","author":"Shcherbinin","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0097","unstructured":"Lilly's donanemab slowed Alzheimer's disease progression in Phase 2 trial: full data presented at AD\/PD\u2122 2021 and published in NEJM. 2021 https:\/\/lilly.mediaroom.com\/2021-03-13-Lillys-donanemab-slowed-Alzheimers-disease-progression-in-Phase-2-trial-full-data-presented-at-AD-PD-TM-2021-and-published-in-NEJM. August 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100458_bib0080","unstructured":"Cavazzoni P. FDA's decision to approve new treatment for Alzheimer's disease. 2021 https:\/\/www.fda.gov\/drugs\/our-perspective\/fdas-decision-approve-new-treatment-alzheimers-disease. September 20, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0095","unstructured":"Lecanemab confirmatory phase 3 CLARITY AD study met primary endpoint, showing highly statistically significant reduction of clinical decline in large global clinical study of 1795 participants with early Alzheimer\u2019s Disease 2022 https:\/\/investors.biogen.com\/news-releases\/news-release-details\/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary. August 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0067","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of Gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0100","unstructured":"[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III GRADUATE programme evaluating gantenerumab in early Alzheimer\u2019s disease. 2022 https:\/\/www.roche.com\/investors\/updates\/inv-update-2022-11-14c. August 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0061","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100458_bib0096","unstructured":"U.S. Food and Drug Administration. FDA converts novel Alzheimer\u2019s Disease treatment to traditional approval. 2023 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval. July 23, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0098","unstructured":"Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease. 2023 https:\/\/lilly.mediaroom.com\/2023-05-03-Lillys-Donanemab-Significantly-Slowed-Cognitive-and-Functional-Decline-in-Phase-3-Study-of-Early-Alzheimers-Disease. August 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0105","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.tjpad.2025.100458_bib0099","unstructured":"U.S. Food and Drug Administration. FDA approves treatment for adults with Alzheimer\u2019s disease. 2024 https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease. July 23, 2025."},{"key":"10.1016\/j.tjpad.2025.100458_bib0051","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0052","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Stat Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0053","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev-statistics-032921-035359","article-title":"Surrogate endpoints in clinical trials","volume":"10","author":"Elliot","year":"2023","journal-title":"Ann Rev Stat Appl"},{"key":"10.1016\/j.tjpad.2025.100458_bib0054","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1541-0420.2008.01106.x","article-title":"Related causal frameworks for surrogate outcomes","volume":"65","author":"Joffe","year":"2009","journal-title":"Biometrics"},{"key":"10.1016\/j.tjpad.2025.100458_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/wics.70014","article-title":"Surrogate Endpoints in drug development: a review of statistical and regulatory perspectives and applications","volume":"17","author":"Chen","year":"2025","journal-title":"WIREs Comput Stat"},{"key":"10.1016\/j.tjpad.2025.100458_bib0056","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"10.1016\/j.tjpad.2025.100458_bib0057","doi-asserted-by":"crossref","unstructured":"Chen T., Hutchinson R.M., Rubel C., Murphy J., Xie J., Montenigro P., et al. A statistical framework for assessing the relationship between biomarkers and clinical endpoints in Alzheimer's Disease. J Prev alzheimers Dis. 2024. https:\/\/doi.org\/10.14283\/jpad.2024.126.","DOI":"10.14283\/jpad.2024.126"},{"key":"10.1016\/j.tjpad.2025.100458_bib0058","series-title":"Evaluation of biomarkers and surrogate endpoints in chronic disease","article-title":"Review: evaluating and regulating biomarker use","year":"2010"},{"key":"10.1016\/j.tjpad.2025.100458_bib0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0062","series-title":"Presented at the 2023 AD\/PD conference","article-title":"A framework to guide statistical approaches for biomarker analysis and relationship to clinical outcomes in Alzheimer\u2019s disease","author":"Chen","year":"2023"},{"key":"10.1016\/j.tjpad.2025.100458_bib0063","article-title":"An insider's perspective on FDA approval of aducanumab","volume":"9","author":"Wang","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.tjpad.2025.100458_bib0064","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/1740774513497125","article-title":"Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers","volume":"10","author":"Sargent","year":"2013","journal-title":"Clin Trials"},{"key":"10.1016\/j.tjpad.2025.100458_bib0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14283\/jpad.2023.6","article-title":"Investigating partially discordant results in phase 3 studies of Aducanumab","volume":"10","author":"Mallinckrodt","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100458_bib0066","series-title":"Presented at Clinical Trials on Alzheimer's Disease (CTAD)","article-title":"Therapeutic reversal of amyloid and tau pathologies in Alzheimer's disease","author":"Nitsch","year":"2022"},{"key":"10.1016\/j.tjpad.2025.100458_bib0068","series-title":"Presented at the American Academy of Neurology (AAN) Annual Meeting","article-title":"GRADUATE I and II: findings of two phase III randomized placebo-controlled studies assessing the efficacy and safety of subcutaneous Gantenerumab in early Alzheimer\u2019s disease (AD)","author":"Smith","year":"2023"},{"key":"10.1016\/j.tjpad.2025.100458_bib0069","unstructured":"Krudys K. FDA Clinical Review. Aduhelm (aducanumab). 2021."},{"key":"10.1016\/j.tjpad.2025.100458_bib0070","series-title":"Presented at the American Society of Neuroradiology (ASNR) Annual Meeting","article-title":"GRADUATE I and II: imaging findings from two phase III trials of subcutaneous gantenerumab in early Alzheimer\u2019s disease with insights on amyloid PET, Tau PET, and volumetric MRI","author":"Barkhof","year":"2023"},{"key":"10.1016\/j.tjpad.2025.100458_bib0072","article-title":"Pooled ENGAGE\/EMERGE integrated placebo-controlled period and long-term extension (LTE) topline results: slower clinical progression at week 134 in aducanumab-treated patients that became amyloid PET negative at week 78","author":"John O\u2019Gorman","year":"2023","journal-title":"Clinical Trials on Alzheimer\u2019s Disease (CTAD)"},{"key":"10.1016\/j.tjpad.2025.100458_bib0073","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.2967\/jnumed.114.153494","article-title":"A semiautomated method for quantification of F 18 florbetapir PET images","volume":"56","author":"Joshi","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0074","series-title":"Presented at Clinical Trials on Alzheimer's Disease (CTAD)","article-title":"GRADUATE I and II: topline results of two global, phase III, randomized, placebo-controlled studies assessing the efficacy and safety of subcutaneous Gantenerumab in early Alzheimer\u2019s disease","author":"Bateman","year":"2022"},{"key":"10.1016\/j.tjpad.2025.100458_bib0076","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/sim.6776","article-title":"Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process","volume":"35","author":"Bujkiewicz","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0077","article-title":"The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence","author":"Aisen","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0078","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/jamainternmed.2020.1097","article-title":"FDA acceptance of surrogate end points for cancer drug approval: 1992-2019","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0079","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100458_bib0081","doi-asserted-by":"crossref","first-page":"n156","DOI":"10.1136\/bmj.n156","article-title":"Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis","volume":"372","author":"Ackley","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.tjpad.2025.100458_bib0082","article-title":"Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis","volume":"378","year":"2022","journal-title":"Bmj"},{"key":"10.1016\/j.tjpad.2025.100458_bib0083","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/alz.12768","article-title":"Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: an instrumental variable meta-analysis","volume":"19","author":"Pang","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100458_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.100988","article-title":"Effects of dose change on the success of clinical trials","volume":"30","author":"Shan","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.tjpad.2025.100458_bib0085","unstructured":"ClinicalTrials.gov. NCT05361382. Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease (HEAD). https:\/\/clinicaltrials.gov\/study\/NCT05361382. September 20, 2024."},{"issue":"9","key":"10.1016\/j.tjpad.2025.100458_bib0086","first-page":"5833","volume":"20","author":"Leuzy","year":"2024","journal-title":"Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: The CenTauR scale and the joint propagation model. Alzheimers Dement."},{"key":"10.1016\/j.tjpad.2025.100458_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101665","article-title":"Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer","volume":"64","author":"Elia","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.tjpad.2025.100458_bib0088","unstructured":"U.S. Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. 2022 https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure. September 18, 2024."},{"key":"10.1016\/j.tjpad.2025.100458_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","author":"Mittal","year":"2024","journal-title":"eClinical Med"},{"key":"10.1016\/j.tjpad.2025.100458_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2022.100364","article-title":"FDA validation of surrogate endpoints in oncology: 2005-2022","volume":"34","author":"Walia","year":"2022","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.tjpad.2025.100458_bib0091","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 study: design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725003991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:24:37Z","timestamp":1776198277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725003991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2274580725003991"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100458","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100458","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100458"}}